HAVA · Harvard Ave Acquisition Corp
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, the Company has a related party receivable of $770,645 and working capital of $225,634. The Company has incurred and expects to continue to incur significant costs in pursuit of its financing and acquisition plans. These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited financial statements are issued. There is no assurance that the Company's plans to consummate a Business Combination will be successful or successful within the required period. The unaudited financial statements do not include any adjustments that might result from the Company's inability to consummate the Business Combination to continue as a going concern.”View the 10-Q filed Jul 29, 2026
Price & Indicators
The closing range uses available history since Dec 15, 2025; less than a full year is stored.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HAVA
this stock
Harvard Ave Acquisition Corp
|
$211.28M | +2.8% | — | — | 0.0% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
CCXI
Churchill Capital Corp XI
|
$686.22M | — | — | — | 6.7% |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$647.37M | +2.7% | — | — | 0.2% |
|
EVAC
EQV Ventures Acquisition Corp. II
|
$602.01M | +2.7% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HAVA | +0.1% | +0.7% | — | +0.0% | +2.8% |
| SPY | +0.3% | +0.6% | +16.7% | +0.8% | +13.4% |
| vs SPY | -0.2% | +0.1% | — | -0.8% | -10.6% |